Methods for monitoring the efficacy of anti-il-2r antibodies...

Details Methods for monitoring the efficacy of anti-il-2r antibodies... Methods for monitoring the efficacy of anti-il-2r antibodies...

G - Physics

01

N

G01N 33/564 (2006.01)

Patent

CA 2759231

The use of HLA-DR+CD4+ T cell counts as biomarker for the efficacy of daclizumab treatment in patients diagnosed with multiple sclerosis.

Cette invention concerne l'utilisation des numérations de cellules HLA-DR+CD4+ T à titre de biomarqueurs pour déterminer l'efficacité du traitement au daclizumab chez des patients atteints de sclérose en plaques.

Affiliated with

Also associated with

Rating

Methods for monitoring the efficacy of anti-il-2r antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for monitoring the efficacy of anti-il-2r antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for monitoring the efficacy of anti-il-2r antibodies... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1342087